Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes Disease Dec 07, 2021
Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022 Nov 29, 2021
Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option Nov 17, 2021
Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights Nov 15, 2021
Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights Nov 12, 2021
Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency Nov 10, 2021
